Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dialive
- Development stage
- Unknown
- Lead developer
- Yaqrit
- Administration
- Intravenous
01
Overview
Dialive is an extracorporeal liver support device developed by Yaqrit for the treatment of patients with acute-on-chronic liver failure (ACLF). The system utilizes a dual-filtration mechanism designed to address the systemic inflammation and organ dysfunction characteristic of ACLF. Specifically, it removes circulating endotoxins, replaces or cleanses dysfunctional albumin, and modulates the cytokine storm. By targeting these key drivers of liver failure, Dialive aims to improve patient survival and facilitate liver recovery or bridge to transplantation.
- Brand names
- Dialive
- Other names
- DialiveYAQ002YAQ-002YAQ 002Liver dialysis
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Dialive.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dialive.